Chapter 2: Overview of biosimilars development

Doi: 10.4155/FSEB2013.14.280 Author LingSing K Chen VP and Global Head of Translational Medicine and Biosimilars QPS Holdings, Newark, Delaware, USA About the Author Dr LingSing Chen is currently serving as Vice President and Global Head of Translational Medicine and Biosimilars at QPS (Delaware, USA), a global GLP- and GCP-compliant CRO supporting Pharma and Biotech companies in discovery, preclinical and clinical drug development worldwide. Since joining QPS in 2005, Dr Chen has played an instrumental role in building and expanding QPS’ capabilities in ligand-binding assays and cell-based assays to assessing PK, immunogenicity, neutralizing antibody activity for large-molecule drug development, as well...